Contrasting AnaptysBio (NASDAQ:ANAB) & AstraZeneca (NASDAQ:AZN)

AstraZeneca (NASDAQ:AZN) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.

Insider & Institutional Ownership

20.4% of AstraZeneca shares are held by institutional investors. 33.7% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares AstraZeneca and AnaptysBio’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	$49.13 billion	5.33	$5.96 billion	$2.04	41.38
AnaptysBio	$30.47 million	30.48	-$163.62 million	($6.14)	-5.54

AstraZeneca has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for AstraZeneca and AnaptysBio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	0	3	6	2	2.91
AnaptysBio	0	2	9	0	2.82

AstraZeneca presently has a consensus price target of $89.75, indicating a potential upside of 6.33%. AnaptysBio has a consensus price target of $50.30, indicating a potential upside of 47.94%. Given AnaptysBio’s higher possible upside, analysts clearly believe AnaptysBio is more favorable than AstraZeneca.

Profitability

This table compares AstraZeneca and AnaptysBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AstraZeneca	13.11%	29.34%	11.15%
AnaptysBio	-711.17%	-161.40%	-35.07%

Volatility and Risk

AstraZeneca has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500.

Summary

AstraZeneca beats AnaptysBio on 11 of the 15 factors compared between the two stocks.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

About AnaptysBio

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.